Dimensional Fund Advisors LP Has $134.40 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Dimensional Fund Advisors LP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.2% during the 1st quarter, HoldingsChannel.com reports. The fund owned 2,079,827 shares of the biopharmaceutical company’s stock after selling 24,330 shares during the period. Dimensional Fund Advisors LP’s holdings in Halozyme Therapeutics were worth $134,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. AlphaCentric Advisors LLC boosted its stake in Halozyme Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 4,794 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 261 shares during the period. SEB Asset Management AB acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $2,243,000. Swiss National Bank lifted its holdings in shares of Halozyme Therapeutics by 0.9% during the first quarter. Swiss National Bank now owns 232,700 shares of the biopharmaceutical company’s stock worth $15,039,000 after buying an additional 2,000 shares during the last quarter. Precision Wealth Strategies LLC boosted its position in shares of Halozyme Therapeutics by 5.8% in the first quarter. Precision Wealth Strategies LLC now owns 7,234 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 397 shares during the period. Finally, California Public Employees Retirement System grew its stake in shares of Halozyme Therapeutics by 9.9% in the first quarter. California Public Employees Retirement System now owns 260,961 shares of the biopharmaceutical company’s stock worth $16,866,000 after acquiring an additional 23,582 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $55,088,215. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 74,102 shares of company stock worth $5,205,798. 2.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $81.48 on Tuesday. The business has a fifty day simple moving average of $73.36 and a 200 day simple moving average of $70.63. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The firm has a market capitalization of $9.66 billion, a price-to-earnings ratio of 29.31, a PEG ratio of 0.34 and a beta of 0.84. Halozyme Therapeutics, Inc. has a one year low of $57.67 and a one year high of $83.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. The business’s revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.